How the LDT Final Rule’s Exemptions Apply to Oncology Labs
Regulatory expert explores whether any exclusions might benefit cancer laboratories trying to navigate upcoming compliance deadlines
Regulatory expert explores whether any exclusions might benefit cancer laboratories trying to navigate upcoming compliance deadlines
How the Eliminating Kickbacks in Recovery Act of 2018 (EKRA) came to be, what laboratory leaders should know about it, and how to comply
Examining DOJ and OIG investigations of labs and their owners: Recent cases show continued focus on the usual enforcement targets.
Laboratory diagnostics manufacturers receive regulatory scrutiny for issues including marketing, quality, and unapproved changes to tests
Key steps to follow when selling your lab to ensure compliance with the Eliminating Kickbacks in Recovery Act of 2018 (EKRA)
When selling your laboratory, in order to remain compliant with federal code, EKRA is something you will want to consider
Outreach and advertising can be tricky prospects for the clinical lab—but the right questions and strategies can help guide your efforts
Key cybersecurity points to address when working with a third party that has access to protected health information
Prenosis claims its test can detect the presence of the often deadly condition within 24 hours of a hospitalization
Cybersecurity expert outlines steps labs and other healthcare providers should take to prepare for future cyberattacks
Know where labs may fall foul of compliance requirements—and discover the actions your lab can take to mitigate the risk of noncompliance